- Non-neuronal cells in amyotrophic lateral sclerosis - from pathogenesis to biomarkers 30 April 2021 Björn F Vahsen
- Hypoxic and pharmacological activation of HIF inhibits SARS-CoV-2 infection of lung epithelial cells 14 April 2021 Peter A C Wing
- The antigenic anatomy of SARS-CoV-2 receptor binding domain 23 March 2021 Wanwisa Dejnirattisai
- Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera 21 March 2021 Piyada Supasa
- Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera 17 March 2021 Daming Zhou
- In vitro Quantitative Imaging Assay for Phagocytosis of Dead Neuroblastoma Cells by iPSC-Macrophages 1 March 2021 Hazel Hall-Roberts
- Breadth and function of antibody response to acute SARS-CoV-2 infection in humans 26 February 2021 Kuan-Ying A Huang
- Molecular and electrophysiological features of spinocerebellar ataxia type seven in induced pluripotent stem cells 24 February 2021 Richard J Burman
- Alzheimer's Risk Gene TREM2 Determines Functional Properties of New Type of Human iPSC-Derived Microglia 22 February 2021 Marvin Reich
- Genome-wide CRISPR/Cas9-knockout in human induced Pluripotent Stem Cell (iPSC)-derived macrophages 20 February 2021 Elena Navarro-Guerrero
Postdoctoral Research Assistant | Janssen Pharmaceutica | firstname.lastname@example.org
Dr. Sharat Warrier is a postdoctoral researched who joined the lab in 2018, to research the role of complement in Alzheimer´s disease.
Alzheimer’s disease (AD) is the most common contributor to dementia. It´s underlying mechanisms are complex, multifactorial, and incompletely understood. It has long been established that neuroinflammation and, more specifically, activation of the complement system, has an important role in pathological processes in AD brains. Complement composed of over 40 interacting proteins, is an ancient and powerful arm of the innate immune system, participating in the recognition, trafficking, elimination of pathogens and misfolded proteins, and maintaining homeostasis. In AD interest over complement stems from the recent large GWA studies which identified >25 genetic risk loci, including several complement associated genes. This is a collaborative industry funded project, jointly supervised by Dr. Sally Cowley at the James Martin Stem Cell Facility, Dr. Elena Di Daniel at the Alzheimer´s Research UK Oxford Drug Discovery Institute and Dr. Louis De Muynck at Janssen pharmaceutica in Belgium. The main goal is to understand the cell type in question for complement expression using iPSC derived cell types of the CNS and the role of the complement proteins in relation to progression of disease.
Sharat graduated with a BSc in Biotechnology where he picked up lab skills with a particular interest in molecular biology techniques. This was followed by a MSc in Industrial and Commercial Biotechnology from Newcastle University in 2009. The research project involved studying and optimising microalgae growth for biofuel production. This was followed by an advanced diploma in Clinical Research and Pharmacovigilance from ICRI, India, to learn and understand the different regulatory processes involved in bringing drugs to market and the downstream safety studies. This was then followed by a PhD at the Ghent University, Belgium with Prof. Petra De Sutter, on understanding the emergence of pluripotency in human embryos and deciphering the role of the different states of pluripotency in human.
His research interests combine stem cell biology, embryology and neuroscience and has been widely published in several peer-reviewed scientific journals. He is passionate about bridging the gap between academia and industry and aims to utilise his analytical, scientific and marketing skill set developed through his education and job experiences to nurture his entrepreneurial and research skill set.